Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study

Romeo Altafini,1 Maria-Luise Scherzer,2 Douglas A Hubatsch,3 Paolo Frezzotti4 1Glaucoma Segment Unit, “San Bortolo” Hospital, Vicenza, Italy; 2Private Practice, Regenstauf, Germany; 3Alcon Laboratories, Inc., Fort Worth, TX, USA; 4Ophthalmic Unit, University of Siena, Siena, Ita...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Altafini R, Scherzer ML, Hubatsch DA, Frezzotti P
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/b75fbe31e7f5461badc301a03f8b8655
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b75fbe31e7f5461badc301a03f8b8655
record_format	dspace
spelling	oai:doaj.org-article:b75fbe31e7f5461badc301a03f8b86552021-12-02T00:13:11ZBrinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study1177-5483https://doaj.org/article/b75fbe31e7f5461badc301a03f8b86552015-12-01T00:00:00Zhttps://www.dovepress.com/brinzolamide-1timolol-versus-dorzolamide-2timolol-in-the-treatment-of--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Romeo Altafini,1 Maria-Luise Scherzer,2 Douglas A Hubatsch,3 Paolo Frezzotti4 1Glaucoma Segment Unit, “San Bortolo” Hospital, Vicenza, Italy; 2Private Practice, Regenstauf, Germany; 3Alcon Laboratories, Inc., Fort Worth, TX, USA; 4Ophthalmic Unit, University of Siena, Siena, Italy Purpose: The objective of this study was to assess preference for fixed-combination brinzolamide 1%/timolol 0.5% (BTFC) versus fixed-combination dorzolamide 2%/timolol 0.5% (DTFC) in patients with open-angle glaucoma or ocular hypertension.Methods: In this prospective, single-masked crossover study, patients were randomized 1:1 to BTFC-DTFC or DTFC-BTFC treatment sequences. Patients self-administered each medication for 7 days, with a 48-hour washout period between treatments, and rated ocular discomfort after each treatment period. Medication preferences based on ocular comfort (primary endpoint) and anticipated adherence were assessed. Safety outcomes included adverse events and intraocular pressure. Between-group differences in treatment preference and ocular discomfort scores were analyzed using chi-square and Wilcoxon–Mann–Whitney tests, respectively. Adherence, intraocular pressure, and adverse events were summarized descriptively.Results: In total, 112 patients were enrolled (mean ± SD age, 66±11 years), and 109 patients completed the study. Numerically, more patients in the intent-to-treat dataset preferred BTFC versus DTFC (59.3% versus 40.7%); however, this result was not statistically significant (treatment difference, 18.6%; P=0.0670). Mean ocular discomfort scores (range, 0–9) were statistically significantly lower with BTFC versus DTFC (2.6 versus 3.7; P=0.0002, Wilcoxon–Mann–Whitney test). More patients who preferred BTFC over DTFC were confident that they would adhere to their preferred medication. Treatment-related adverse events included blurred vision with BTFC and eye irritation or eye pain with DTFC.Conclusion: BTFC and DTFC were preferred by approximately 60% and 40% of patients, respectively, and BTFC was associated with less patient-reported ocular discomfort. Greater ocular comfort of glaucoma medications may improve treatment adherence. Keywords: brinzolamide, dorzolamide, fixed combination, ocular discomfort, patient preferenceAltafini RScherzer MLHubatsch DAFrezzotti PDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2015, Iss default, Pp 2263-2270 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Altafini R Scherzer ML Hubatsch DA Frezzotti P Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study
description	Romeo Altafini,1 Maria-Luise Scherzer,2 Douglas A Hubatsch,3 Paolo Frezzotti4 1Glaucoma Segment Unit, “San Bortolo” Hospital, Vicenza, Italy; 2Private Practice, Regenstauf, Germany; 3Alcon Laboratories, Inc., Fort Worth, TX, USA; 4Ophthalmic Unit, University of Siena, Siena, Italy Purpose: The objective of this study was to assess preference for fixed-combination brinzolamide 1%/timolol 0.5% (BTFC) versus fixed-combination dorzolamide 2%/timolol 0.5% (DTFC) in patients with open-angle glaucoma or ocular hypertension.Methods: In this prospective, single-masked crossover study, patients were randomized 1:1 to BTFC-DTFC or DTFC-BTFC treatment sequences. Patients self-administered each medication for 7 days, with a 48-hour washout period between treatments, and rated ocular discomfort after each treatment period. Medication preferences based on ocular comfort (primary endpoint) and anticipated adherence were assessed. Safety outcomes included adverse events and intraocular pressure. Between-group differences in treatment preference and ocular discomfort scores were analyzed using chi-square and Wilcoxon–Mann–Whitney tests, respectively. Adherence, intraocular pressure, and adverse events were summarized descriptively.Results: In total, 112 patients were enrolled (mean ± SD age, 66±11 years), and 109 patients completed the study. Numerically, more patients in the intent-to-treat dataset preferred BTFC versus DTFC (59.3% versus 40.7%); however, this result was not statistically significant (treatment difference, 18.6%; P=0.0670). Mean ocular discomfort scores (range, 0–9) were statistically significantly lower with BTFC versus DTFC (2.6 versus 3.7; P=0.0002, Wilcoxon–Mann–Whitney test). More patients who preferred BTFC over DTFC were confident that they would adhere to their preferred medication. Treatment-related adverse events included blurred vision with BTFC and eye irritation or eye pain with DTFC.Conclusion: BTFC and DTFC were preferred by approximately 60% and 40% of patients, respectively, and BTFC was associated with less patient-reported ocular discomfort. Greater ocular comfort of glaucoma medications may improve treatment adherence. Keywords: brinzolamide, dorzolamide, fixed combination, ocular discomfort, patient preference
format	article
author	Altafini R Scherzer ML Hubatsch DA Frezzotti P
author_facet	Altafini R Scherzer ML Hubatsch DA Frezzotti P
author_sort	Altafini R
title	Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study
title_short	Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study
title_full	Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study
title_fullStr	Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study
title_full_unstemmed	Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study
title_sort	brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/b75fbe31e7f5461badc301a03f8b8655
work_keys_str_mv	AT altafinir brinzolamide1timololversusdorzolamide2timololinthetreatmentofopenangleglaucomaorocularhypertensionprospectiverandomizedpatientpreferencestudy AT scherzerml brinzolamide1timololversusdorzolamide2timololinthetreatmentofopenangleglaucomaorocularhypertensionprospectiverandomizedpatientpreferencestudy AT hubatschda brinzolamide1timololversusdorzolamide2timololinthetreatmentofopenangleglaucomaorocularhypertensionprospectiverandomizedpatientpreferencestudy AT frezzottip brinzolamide1timololversusdorzolamide2timololinthetreatmentofopenangleglaucomaorocularhypertensionprospectiverandomizedpatientpreferencestudy
_version_	1718403885739016192

Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study

Ejemplares similares